Zacks.com on MSN17h
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLAReplimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...
21h
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback